QRG Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

QRG Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.02M	Buy	89,078 +12,925	+17%	+$430K	0.03%	383
2026 Q1	$2.29M	Buy	76,153 +3,580	+5%	+$115K	0.02%	398
2025 Q4	$2.27M	Buy	72,573 +31	+0%	+$764	0.03%	391
2025 Q3	$1.47M	Sell	72,542 -58,327	-45%	-$1.02M	0.02%	446
2025 Q2	$2.19M	Buy	130,869 +1,439	+1%	+$23.2K	0.02%	458
2025 Q1	$1.99M	Sell	129,430 -18,708	-13%	-$334K	0.02%	454
2024 Q4	$3.26M	Buy	148,138 +5,556	+4%	+$101K	0.03%	376
2024 Q3	$2.57M	Sell	142,582 -2,356	-2%	-$41.2K	0.03%	406
2024 Q2	$2.36M	Buy	144,938 +1,191	+0.8%	+$18.3K	0.03%	384
2024 Q1	$2.03M	Buy	143,747 +50,247	+54%	+$633K	0.03%	416
2023 Q4	$976K	Buy	93,500 +8,680	+10%	+$81K	0.01%	539
2023 Q3	$865K	Buy	+84,820	New	+$790K	0.02%	522

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

QRG Capital Management's TEVA Position: Q2 2026 in Review

QRG Capital Management increased its Teva Pharmaceuticals (TEVA) stake by 17% in Q2 2026, buying an estimated $430K and bringing the position to 89,078 shares worth $3.02M. The position accounts for 0.03% of the portfolio, ranked #383.

QRG Capital Management first reported a position in TEVA in Q3 2023 and has held it in 12 quarters since. The position peaked at $3.26M in Q4 2024. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

QRG Capital Management held 89,078 shares of Teva Pharmaceuticals worth $3.02M as of Q2 2026.
QRG Capital Management bought 12,925 Teva Pharmaceuticals shares in Q2 2026, an estimated $430K.
Teva Pharmaceuticals made up 0.03% of QRG Capital Management's portfolio in Q2 2026, its #383 holding.
QRG Capital Management first reported a position in Teva Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
QRG Capital Management's Teva Pharmaceuticals position peaked at $3.26M in Q4 2024.
673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on QRG Capital Management's 13F filing for Q2 2026, filed 14 Jul 2026.